Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KYNU | Q16719 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27933271 | 0.73 | PLCG1 (0.51) | PLCG1TSHRKMT2APOLBTDP1 | |
| SCHEMBL29483741 | 0.72 | TSHR (0.49) | TP53TSHRKMT2AMEN1POLB | |
| SCHEMBL8463735 | 0.72 | ALDH1A1 (0.64) | TP53TSHRKMT2AMEN1TDP1 | |
| SCHEMBL14362156 | 0.70 | TSHR (0.57) | TP53TSHRKMT2AMEN1MAPT | |
| SCHEMBL6203315 | 0.69 | PLCG1 (0.44) | PLCG1TSHRPOLBTDP1NPC1 | |
| SCHEMBL21647766 | 0.69 | TSHR (0.45) | TP53TSHRKMT2AMEN1TDP1 | |
| SCHEMBL28911450 | 0.68 | PLCG1 (0.56) | PLCG1KMT2AMEN1MAPTPOLB | |
| SCHEMBL3791059 | 0.66 | TSHR (0.57) | TP53TSHRKMT2AMEN1MAPT | |
| SCHEMBL28957581 | 0.66 | ALDH1A1 (0.48) | TP53TSHRKMT2AMEN1 | |
| SCHEMBL4250234 | 0.66 | PLCG1 (1.00) | PLCG1KMT2AMEN1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425279-A4 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | SEARLE LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050090543-A1 | Method for the preparation of tetrahydrobenzothiepines | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | US | disclosed |
| US-6794544-B2 | APICAL SODIUM CO- DEPENDENT BILE ACID TRANSPORTER (ASBT) INHIBITORS | PHARMACIA CORPORATION | 2004-09-21 | — | — | US | disclosed |
| EP-1425279-A2 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | G.D. Searle LLC (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20040082647-A1 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE, LLC | 2004-04-29 | — | — | US | disclosed |
| US-20030236406-A1 | Method for the preparation of tetrahydrobenzothiepines | BABIAK KEVIN A (US) | 2003-12-25 | — | — | US | disclosed |
| WO-2003022804-A9 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | SEARLE LLC (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030199515-A1 | Method for the preparation of crystalline tetrahydrobenzothiepines | G.D. SEARLE, LLC (US) | 2003-10-23 | — | — | US | disclosed |
| US-6586434-B2 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE, LLC | 2003-07-01 | — | — | US | disclosed |
| WO-2003022804-A2 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | G.D. SEARLE LLC (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1286984-A2 | METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES | Pharmacia Corporation (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020032329-A1 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE LLC | 2002-03-14 | — | — | US | disclosed |
| WO-2001068637-A2 | METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199515-A1 | Method for the preparation of crystalline tetrahydrobenzothiepines | TPMT, MPST, SULT1A1 | PLCG1 3870/4885NPSR1 3308/4885TP53 3864/4885 |
| US-20020032329-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | PLCG1 3678/4885NPSR1 3049/4885TP53 3509/4885 |
| US-20050090543-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | PLCG1 3678/4885NPSR1 3049/4885TP53 3509/4885 |
| US-20030236406-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | PLCG1 3672/4885NPSR1 3043/4885TP53 3497/4885 |
| US-20040082647-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | PLCG1 3678/4885NPSR1 3049/4885TP53 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.